Branding Campaign, Asset Sale, Executive Promotion, Clinical Data Presentation, and Drug Approval Update - Research Reports on Synchrony Financial, Avalonbay, Aflac, Teva and AstraZeneca

NEW YORK, October 7, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Synchrony Financial (NYSE: SYF), Avalonbay Communities Inc. (NYSE: AVB), Aflac Inc. (NYSE: AFL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and AstraZeneca PLC (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6959-100free.

--
Synchrony Financial Research Reports
On September 22, 2014, Synchrony Financial announced the launch of a nationwide advertising campaign to promote its new brand identity. According to Synchrony Financial, the branding campaign, which aims to help the new name of the Company reach key industries where it has a deep presence, will include multiple channels - Print ads in the Wall Street Journal, The New York Times and trade publications; TV on network and cable news and sports programming; Airport advertising; and Digital ads across multiple properties. Margaret Keane, President and CEO of Synchrony Financial, said, "After conducting extensive research with key stakeholders, we are proud to launch a Synchrony Financial brand campaign that truly represents who we are as a company and the value proposition we offer to our stakeholders." The Company reportedly partnered with Interbrand on the development of its new branding. The full research reports on Synchrony Financial are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/SYF/report.pdf

--
Avalonbay Communities Inc. Research Reports
On September 15, 2014, Avalonbay Communities Inc. (Avalonbay) announced the disposition of Avalon Chrystie Place (Avalon Chrystie), which is a 361 unit apartment home community located in New York, for a gross sales price of $365 million. According to the Company, it owned a 20% joint venture interest in Avalon Chrystie and expects to receive net proceeds of $108 million from the sell-off, subject to the wind-down of the joint-venture. Avalonbay informed that the expected net proceeds amount includes an anticipated receipt of $50 million of distributions in respect of its 20% joint venture interest, and a receipt of $58 million of distributions in respect of its promoted interest. The full research reports on Avalonbay are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/AVB/report.pdf

--
Aflac Inc. Research Reports
On September 29, 2014, Aflac Inc. (Aflac) reported the promotions of Teresa L. White to the role of President, Aflac U.S., and of Kenneth S. Janke, the former President of Aflac U.S., to the deputy CFO role. According to Aflac, White, in her new role, will be responsible for Aflac Group operations in Columbia, S.C. and will report to Janke. In the deputy CFO role, Janke, who is also the Executive Vice President of Aflac, will assume additional responsibilities to include the financial reporting and actuarial functions. Janke is also responsible for the Company's strategy function and will continue to report to Kriss Cloninger III. Dan Amos, CEO at Aflac, said, "Our realignment in 2013 has successfully accomplished what it was designed to do, which was in part to grow our leadership bench, and that coupled with Ken and Teresa's outstanding performance is why we are able to make these announcements today." The full research reports on Aflac are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/AFL/report.pdf

--
Teva Pharmaceutical Industries Ltd. Research Reports
On September 12, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced the presentation of the Gene Expression Analysis data at the 2014: Joint ACTRIMS-ECTRIMS Meeting, which demonstrated differences between gene expression profiles of Teva's COPAXONE® (glatiramer acetate injection) and other glatiramer acetate products. According to the Company, as part of the research, a human monocyte cell line was stimulated by either COPAXONE® or another glatiramer acetate product from several manufacturers, which revealed the aforesaid difference in gene expression profiles and the same was subsequently confirmed by a quantitative laboratory test (qRT-PCR). Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva, said, "Teva believes that this analysis suggests that additional studies are needed in order to ensure that other glatiramer acetate products have a similar biologic effect as COPAXONE®." The full research reports on Teva are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/TEVA/report.pdf

--
AstraZeneca PLC Research Reports
On September 26, 2014, AstraZeneca PLC (AstraZeneca) announced that its MOVENTIG® (naloxegol), an investigational, peripherally-acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s), has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). According to the Company, CHMP's recommendation for the approval of MOVENTIG® comes after a review of comprehensive data from the KODIAC clinical programme that comprised of four studies assessing the safety and efficacy of MOVENTIG. The CHMP's positive opinion on MOVENTIG will be reviewed by the European Commission (EC), and if approved MOVENTIG will be the first once-daily, oral PAMORA to be available in all 28 European Union member countries along with Iceland and Norway. The full research reports on AstraZeneca are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/AZN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review